🟢 Citius Pharmaceuticals is trading 6.5% up in pre-market on 78% growth in new LYMPHIR ordering sites

Citius Pharmaceuticals is trading 6.52% up at $0.73 after updates showed stronger LYMPHIR commercial adoption and expanding institutional demand.

• New institutions ordering LYMPHIR increased 78% quarter over quarter to 42 sites.
• Vial orders rose 31% for the quarter ended June 30, 2026.
• Investors are positioning ahead of the expected August 11, 2026, earnings report, focused on revenue growth and LYMPHIR’s commercial trajectory.